Beigene一个生物医药公司,应该是做最后期的研发了前期的临床。 有美国大医药公司的投资!不错啊,他都跳了。 http://www.businessweek.com/news/2011-05-25/china-s-cancer-deat Wang Xiaodong, a naturalized U.S. citizen who founded BeiGene with Oyler, said he gave up posts at the U.S.-based Howard Hughes Medical Institute and a professorship at the University of Texas-Southwestern to return to China in 2003. He helped the Chinese government establish and expand the government-funded National Institute of Biological Sciences, which now has 800 researchers. “I was in the U.S. for 26 years and built my entire academic career there, ” said Wang, 48, who has remained the Beijing institute’s director, in an interview. “The most innate motivation coming back is to be part of what’s happening in China, which by any stretch of imagination is the most dramatic event in human history in the last 30 years.” Sophisticated Science More Chinese scientists are returning from abroad to work in China, attracted by more sophisticated research, including the development of biotechnology that make drugs from proteins produced by living cells, said McKinsey’s Wang. Previously, pharmaceutical jobs in China were mainly in sales and marketing, she said. Wang Xiaodong and Oyler’s own money provided initial financing for BeiGene. Oyler declined to say how much Whitehouse Station, New Jersey-based Merck has invested, adding that the backing may lead to partnership deals.